Surrozen, Inc.
SRZN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001824893
In the last 90 days, Surrozen, Inc. insiders filed 0 open-market purchases and 1 sale; 70 institutions reported holding it in 13F filings for Q2 2026, worth $314.5M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Surrozen, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 21 | 2 | 23 | +4 |
| Shares | 2.11M | 70.6K | 2.13M | +96.0K (+4.7%) |
| Value | $23.1M | $772.9K | $25.5M | +$3.20M (+14.4%) |
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (6)
Institutions that held Surrozen, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Heights Capital Management, Inc | 29,999 | $353.1K | 0.26% |
| Price T Rowe Associates Inc | 21,715 | $256.0K | 0.00% |
| Citadel Advisors LLC | 10,930 | $128.6K | 0.00% |
| BlackRock, Inc. | 8,211 | $98.4K | 0.00% |
| Tower Research Capital LLC (TRC) | 455 | $5.45K | 0.00% |
| Barclays PLC | 25 | $300 | 0.00% |
Sold out (2)
Institutions that held Surrozen, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| UBS Group AG | 12,027 | $131.7K |
| Royal Bank of Canada | 338 | $4.00K |
Not filed for Q3 2024 yet (2)
Institutions that held Surrozen, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| CVI Holdings, LLC | 64,905 | $710.7K |
| BlackRock Inc. | 5,679 | $62.2K |